Once-Monthly Olanzapine Shot Drops the Three-Hour Watch, but Clinics Still Own Adherence

Olanzapine is one of the most effective antipsychotics for schizophrenia, and for more than a decade its long-acting injectable form has been one of the hardest to use. Every dose of the intramuscular version comes with a three-hour wait in a certified clinic, under observation, followed by an escort home. On October 9 the FDA approved a way around that. Teva's Weltruza (olanzapine) extended-release injectable suspension is a once-monthly subcutaneous shot that needs no loading dose, no oral supplementation and no post-injection monitoring. It removes the single biggest logistical barrier to long-acting olanzapine. It does not remove the reason long-acting injectables of every kind are still used by a small minority of patients.

What the FDA Approved, and What It Left Behind

Weltruza comes in three strengths, 318 mg, 425 mg and 531 mg, which correspond to daily oral olanzapine doses of 10, 15 and 20 mg. It uses SteadyTeq, a copolymer delivery technology from Medincell, to release the drug steadily over the month. Teva says it will reach US pharmacies "in the coming weeks," and the European Medicines Agency accepted a marketing application for the same product in May. Teva estimates that about 2.1 million people in the US are diagnosed with schizophrenia, and that about 80% of patients relapse multiple times in their first five years of treatment.

The comparison that matters is with the existing intramuscular product. Its US prescribing information describes post-injection delirium/sedation syndrome, with symptoms consistent with olanzapine overdose, in fewer than 0.1% of injections and about 2% of patients treated for up to 46 months. Because of that risk, the drug can only be given in a registered facility with ready access to emergency services. A clinician must continuously observe the patient for at least three hours after each injection, and every patient must be accompanied to their destination when they leave. For a community mental health center, that means a chair, a staff member and a ride for every single dose.

The new label does not erase the concern entirely. It still carries a warning that the syndrome has occurred with an intramuscular olanzapine product and that it is unknown whether it can occur with the subcutaneous form, along with the boxed warning about increased mortality in elderly patients with dementia-related psychosis that applies to the drug class.

The SOLARIS Evidence

The approval rests on SOLARIS, a multinational Phase 3 trial in adults aged 18 to 64. In its first eight weeks, 675 patients with acute exacerbations were randomized equally to low, medium or high doses of the injectable or to placebo. In a second period of 48 weeks, placebo completers were moved onto active treatment to assess long-term safety. AJMC reported that the reduction in PANSS total score versus placebo at week eight was 9.75 points for the 318 mg dose, 11.27 points for 425 mg and 9.76 points for 531 mg, and all three doses also beat placebo on illness severity and on personal and social functioning scores.

Tolerability looked like oral olanzapine. The most common adverse events were weight gain, sleepiness, headache, constipation and injection site reactions, and the label notes clinically significant weight gain and metabolic changes consistent with the oral drug. Discontinuations due to adverse events were 5% on treatment against 4% on placebo. The headline safety number is the one the label could not ignore: Psychiatric Times reported that no post-injection delirium/sedation cases were observed or confirmed across 3,971 injections in the program. Christoph Correll, a psychiatry professor at the Zucker School of Medicine at Hofstra/Northwell, called adherence "a major barrier to stability," particularly for patients on daily oral medication.

Why Removing the Watch Is Not Enough

Long-acting injectables have a strong case, and they are still rarely used. A study in Neuropsychiatric Disease and Treatment, reported by HCPLive, followed adults with schizophrenia in the MedStar Health system in the Baltimore and Washington, DC area from 2017 to 2021. Only 9.0% received a second-generation long-acting injectable, and older patients and Medicaid beneficiaries had the lowest use. Those are the groups for whom a missed daily pill is most likely to end in a relapse and a hospital bed.

A monthly shot changes the adherence problem rather than solving it. With a daily pill, missed doses are invisible until symptoms return. With a monthly injection, a missed appointment is visible on the day it happens, which is only useful if someone is watching the schedule and has the capacity to follow up. Schizophrenia typically begins in the late teens to early 20s for men and the late 20s to early 30s for women, so the first injections often fall during a period when patients are still living with, and relying on, family members who help manage care. And because olanzapine carries the same weight gain and metabolic risk in every form, monthly psychiatric visits do not replace regular metabolic monitoring, which usually falls to primary care.

A Playbook for Sponsors, Providers and Payers

• Redesign the injection visit. Without the three-hour observation, an olanzapine injection can fit into an ordinary clinic slot, so the existing protocols and room bookings built around the REMS should be revisited.
• Track missed doses as a clinical event. A late monthly injection is the clearest early warning of relapse risk, and clinics need a named owner and an outreach plan for every missed appointment.
• Use virtual visits between injections. Telepsychiatry check-ins can keep patients engaged during the month without adding in-person visits for people who struggle with transport.
• Hand metabolic monitoring to primary care, explicitly. Weight, glucose and lipid checks should be scheduled and shared, not assumed, because the injectable carries the oral drug's metabolic risks.
• Involve families early. Patients in their late teens and early 20s often depend on parents or relatives to keep appointments, and caregiver support is part of keeping the monthly schedule intact.
• Make the payer case on relapse, not convenience. With no price disclosed, sponsors should build evidence on hospitalizations avoided among Medicaid and older patients, the groups that use injectables least.

Weltruza fixes a real regulatory burden. For more than a decade, a three-hour observation rule kept one of the most effective antipsychotics out of reach as a long-acting option, and that rule no longer applies to this product. But the low use of long-acting injectables was never only about olanzapine's REMS. It reflects how hard it is to keep people with schizophrenia connected to care month after month. The clinics, care teams and payers that build for the next appointment, not just the first injection, will decide whether this approval changes outcomes.